Forsøksdyr: Combining RIAD and CAR T cell therapy

Godkjenningsdato 07.09.2018

Godkjenningsperiode 07.09.2018-31.12.2021

One of the major obstacles for current cancer immunotherapy is the immunosuppressive tumor microenvironment (TME) allowing tumor cells to escape immunosurveillance and anti-tumor immunity. Two components of the TME, prostaglandin E2 and adenosine, targets the cAMP immunomodulating signaling pathway leading to retarded immune response. Here, we will evaluate tumor development in mice treated with chimeric antigen receptor T cells in combination with a peptide that block this immunomodulating cAMP signalling. Our goal is thus to reveal potential synergistic effects of anti-tumor immune activity in combinatorial immune treatments.